|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
|
EA001595B1
(ru)
|
1996-04-12 |
2001-06-25 |
Варнер-Ламберт Компани |
Необратимые ингибиторы тирозинкиназ
|
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
|
CN1102593C
(zh)
|
1996-06-27 |
2003-03-05 |
詹森药业有限公司 |
N－[4－(杂芳基甲基)苯基]－杂芳基胺类化合物
|
|
WO1998013350A1
(en)
|
1996-09-25 |
1998-04-02 |
Zeneca Limited |
Qinoline derivatives inhibiting the effect of growth factors such as vegf
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
GB9708265D0
(en)
*
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
|
IL139641A0
(en)
|
1998-05-28 |
2002-02-10 |
Parker Hughes Inst |
Quinazolines for treating brain tumor
|
|
PT1107964E
(pt)
|
1998-08-11 |
2010-06-11 |
Novartis Ag |
Derivados de isoquinolina com actividade inibidora da angiogénese
|
|
KR20010089171A
(ko)
|
1998-08-21 |
2001-09-29 |
추후제출 |
퀴나졸린 유도체
|
|
CA2361174C
(en)
|
1999-02-27 |
2009-10-27 |
Boehringer Ingelheim Pharma Kg |
4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
|
|
DE19911509A1
(de)
*
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6258820B1
(en)
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
|
YU13200A
(sh)
*
|
1999-03-31 |
2002-10-18 |
Pfizer Products Inc. |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
|
US6126917A
(en)
*
|
1999-06-01 |
2000-10-03 |
Hadasit Medical Research Services And Development Ltd. |
Epidermal growth factor receptor binding compounds for positron emission tomography
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
JP2003504363A
(ja)
*
|
1999-07-09 |
2003-02-04 |
グラクソ グループ リミテッド |
プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
|
|
CA2384291A1
(en)
*
|
1999-09-21 |
2001-03-29 |
Astrazeneca Ab |
Quinazoline derivatives and their use as pharmaceuticals
|
|
CA2384282A1
(en)
*
|
1999-09-21 |
2001-03-29 |
Astrazeneca Ab |
Quinazoline compounds and pharmaceutical compositions containing them
|
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
|
KR100881105B1
(ko)
*
|
1999-11-05 |
2009-02-02 |
아스트라제네카 아베 |
Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
|
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
|
AU2001235804A1
(en)
|
2000-03-06 |
2001-09-17 |
Astrazeneca Ab |
Therapy
|
|
KR100675252B1
(ko)
*
|
2000-03-08 |
2007-02-08 |
한국생명공학연구원 |
신규 7,8-디히드로-잔테논-8-카르복실산 유도체 및 이를생산하는 신규 미생물
|
|
US20070021392A1
(en)
*
|
2000-03-31 |
2007-01-25 |
Davis Peter D |
Divided dose therapies with vascular damaging activity
|
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
|
ES2267748T3
(es)
*
|
2000-04-07 |
2007-03-16 |
Astrazeneca Ab |
Compuestos de quinazolina.
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
|
TWI317285B
(en)
*
|
2000-07-28 |
2009-11-21 |
Dainippon Sumitomo Pharma Co |
New use and kit for remedies for cancer
|
|
WO2002016352A1
(en)
|
2000-08-21 |
2002-02-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
|
JP4564713B2
(ja)
|
2000-11-01 |
2010-10-20 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
|
|
BR0116452A
(pt)
|
2000-12-21 |
2003-09-30 |
Glaxo Group Ltd |
Composto, composição farmacêutica, uso de um composto
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
JP2002293773A
(ja)
*
|
2001-03-30 |
2002-10-09 |
Sumika Fine Chemicals Co Ltd |
キナゾリン誘導体の製造方法
|
|
WO2002092579A1
(en)
*
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
4-anilinoquinazoline derivatives
|
|
US7132427B2
(en)
|
2001-06-21 |
2006-11-07 |
Ariad Pharmaceuticals, Inc. |
Quinazolines and uses thereof
|
|
AR037438A1
(es)
*
|
2001-11-27 |
2004-11-10 |
Wyeth Corp |
3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
|
|
SI1474420T1
(sl)
|
2002-02-01 |
2012-06-29 |
Astrazeneca Ab |
Spojine kinazolina
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
US7576074B2
(en)
*
|
2002-07-15 |
2009-08-18 |
Rice Kenneth D |
Receptor-type kinase modulators and methods of use
|
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
|
WO2004018435A1
(en)
|
2002-08-24 |
2004-03-04 |
Astrazeneca Ab |
Pyrimidine derivatives as modulators of chemokine receptor activity
|
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
|
AU2003278383B2
(en)
|
2002-11-04 |
2007-06-14 |
Astrazeneca Ab |
Quinazoline derivatives as Src tyrosine kinase inhibitors
|
|
US7488823B2
(en)
*
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
|
WO2004046101A2
(en)
*
|
2002-11-20 |
2004-06-03 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
|
|
SI1847539T1
(sl)
|
2002-12-24 |
2010-01-29 |
Astrazeneca Ab |
Kinazolinski derivati
|
|
CA2514479A1
(en)
*
|
2003-01-23 |
2004-08-05 |
T.K. Signal Ltd. |
Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
|
|
TWI422583B
(zh)
|
2003-03-07 |
2014-01-11 |
參天製藥股份有限公司 |
具有以４-吡啶烷硫基為取代基之新穎化合物
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
DK1660090T3
(da)
*
|
2003-08-14 |
2012-12-17 |
Array Biopharma Inc |
Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
|
|
ATE395346T1
(de)
|
2003-09-16 |
2008-05-15 |
Astrazeneca Ab |
Chinazolinderivate als tyrosinkinaseinhibitoren
|
|
AU2004272346A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
EP2210607B1
(en)
*
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
CN1905873A
(zh)
|
2003-11-19 |
2007-01-31 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
|
ATE501138T1
(de)
|
2004-01-05 |
2011-03-15 |
Astrazeneca Ab |
Thiophenderivate als chk-1-inhibitoren
|
|
DE602005010824D1
(de)
|
2004-02-03 |
2008-12-18 |
Astrazeneca Ab |
Chinazolinderivate
|
|
BRPI0507757A
(pt)
|
2004-02-17 |
2007-07-10 |
Santen Pharmaceutical Co Ltd |
composto, composição farmacêutica, e agente terapêutico para uma doença na qual a angiogênese ou a hipermeabilidade vascular está envolvida
|
|
KR20080095915A
(ko)
*
|
2004-05-06 |
2008-10-29 |
워너-램버트 캄파니 엘엘씨 |
4-페닐아미노-퀴나졸린-6-일-아미드
|
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
|
EP2311827A1
(en)
|
2004-08-28 |
2011-04-20 |
AstraZeneca AB |
Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
|
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
|
ZA200705695B
(en)
|
2004-12-21 |
2009-02-25 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
BRPI0606793A8
(pt)
|
2005-02-04 |
2018-03-13 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
|
|
ES2351613T3
(es)
*
|
2005-03-03 |
2011-02-08 |
Santen Pharmaceutical Co., Ltd. |
Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
|
|
EP1864977B1
(en)
|
2005-03-31 |
2015-07-29 |
Santen Pharmaceutical Co., Ltd. |
Novel cyclic compound having pyrimidinylalkylthio group
|
|
CN1858040B
(zh)
*
|
2005-05-08 |
2011-04-06 |
中国科学院上海药物研究所 |
5,8-二取代喹唑啉及其制备方法和用途
|
|
CN101175734B
(zh)
*
|
2005-05-12 |
2011-10-12 |
黄文林 |
一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
|
|
CN101175733A
(zh)
*
|
2005-05-12 |
2008-05-07 |
黄文林 |
一种酪氨酸激酶抑制剂、其制备方法及作为抗肿瘤药物的应用
|
|
WO2006119673A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
|
|
DE112005003498T5
(de)
*
|
2005-05-12 |
2008-03-27 |
Wenlin Huang |
Herstellungsverfahren für Chinazolinderivate und Anwendung zur Herstellung zur Behandlung von Tumorerkrankungen
|
|
ES2405785T3
(es)
|
2005-05-18 |
2013-06-03 |
Array Biopharma Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
|
CN1313449C
(zh)
*
|
2005-07-14 |
2007-05-02 |
沈阳中海生物技术开发有限公司 |
新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
|
|
JP2009501793A
(ja)
|
2005-07-21 |
2009-01-22 |
アストラゼネカ・アクチエボラーグ |
新規ピペリジン誘導体
|
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
|
ATE488513T1
(de)
|
2005-09-20 |
2010-12-15 |
Astrazeneca Ab |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
JPWO2007034881A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
JPWO2007034882A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
EP1939200A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
|
US20090105212A1
(en)
|
2005-09-22 |
2009-04-23 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
|
EP1937632A1
(en)
|
2005-10-06 |
2008-07-02 |
Astra Zeneca AB |
Novel compounds
|
|
US8247556B2
(en)
|
2005-10-21 |
2012-08-21 |
Amgen Inc. |
Method for preparing 6-substituted-7-aza-indoles
|
|
JP2009513615A
(ja)
|
2005-10-28 |
2009-04-02 |
アストラゼネカ アクチボラグ |
癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
|
|
ATE446294T1
(de)
|
2005-11-15 |
2009-11-15 |
Array Biopharma Inc |
N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
|
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
|
DK1979001T3
(da)
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
|
TW200732296A
(en)
|
2005-12-15 |
2007-09-01 |
Astrazeneca Ab |
Novel compounds
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
JP2009538289A
(ja)
|
2006-05-26 |
2009-11-05 |
アストラゼネカ・アクチエボラーグ |
ビアリールまたはヘテロアリール置換インドール
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
|
CA2659851C
(en)
|
2006-08-23 |
2014-02-25 |
Kudos Pharmaceuticals Limited |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
|
AU2007296746B2
(en)
*
|
2006-09-11 |
2012-07-05 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
WO2008033747A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Curis, Inc. |
Multi-functional small molecules as anti-proliferative agents
|
|
US7547781B2
(en)
*
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
US7799954B2
(en)
|
2006-11-17 |
2010-09-21 |
Abraxis Bioscience, Llc |
Dicarbonyl derivatives and methods of use
|
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
|
ATE555111T1
(de)
|
2006-12-19 |
2012-05-15 |
Astrazeneca Ab |
Chinuclidinol-derivate als muscarinrezeptor- antagonisten
|
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
|
WO2008093677A1
(ja)
|
2007-01-29 |
2008-08-07 |
Santen Pharmaceutical Co., Ltd. |
血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
|
|
AU2008212999A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
|
JPWO2008114819A1
(ja)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
|
US8119616B2
(en)
*
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
WO2009035718A1
(en)
*
|
2007-09-10 |
2009-03-19 |
Curis, Inc. |
Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
|
|
EA201000436A1
(ru)
|
2007-10-04 |
2010-10-29 |
Астразенека Аб |
Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
|
|
PL2201012T3
(pl)
|
2007-10-11 |
2014-11-28 |
Astrazeneca Ab |
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
|
|
US8080558B2
(en)
|
2007-10-29 |
2011-12-20 |
Natco Pharma Limited |
4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
|
|
JP5421925B2
(ja)
|
2007-12-19 |
2014-02-19 |
ジェネンテック， インコーポレイテッド |
５−アニリノイミダゾピリジン及び使用の方法
|
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
|
KR101759457B1
(ko)
|
2007-12-21 |
2017-07-31 |
메디뮨 리미티드 |
인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
US8497369B2
(en)
|
2008-02-07 |
2013-07-30 |
Boehringer Ingelheim International Gmbh |
Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
|
|
WO2009108670A1
(en)
|
2008-02-28 |
2009-09-03 |
Merck Serono S.A. |
Protein kinase inhibitors and use thereof
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
JP5739802B2
(ja)
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
|
|
MX2010012492A
(es)
|
2008-05-27 |
2010-12-21 |
Astrazeneca Ab |
Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
|
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
|
CN101619043B
(zh)
*
|
2008-06-30 |
2013-06-05 |
和记黄埔医药（上海）有限公司 |
喹唑啉衍生物及其医药用途
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
EP2313397B1
(de)
|
2008-08-08 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
|
BRPI0923504A2
(pt)
|
2008-12-11 |
2020-05-26 |
Axcentua Pharmaceuticals Ab |
Formas cristalinas de genisteína.
|
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
|
WO2010077530A1
(en)
|
2008-12-17 |
2010-07-08 |
Merck Patent Gmbh |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
|
AU2009336040B2
(en)
|
2008-12-18 |
2015-07-16 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
NZ779754A
(en)
|
2009-01-16 |
2023-04-28 |
Exelixis Inc |
Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
RU2683325C2
(ru)
|
2009-02-05 |
2019-03-28 |
Иммьюноджен, Инк. |
Новые производные бензодиазепина
|
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
|
MX2011008452A
(es)
|
2009-02-10 |
2011-12-16 |
Astrazeneca Ab |
Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
|
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
|
WO2011035540A1
(zh)
|
2009-09-28 |
2011-03-31 |
齐鲁制药有限公司 |
作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
|
|
AU2010302420B2
(en)
|
2009-10-02 |
2013-07-04 |
Astrazeneca Ab |
2-pyridone compounds used as inhibitors of neutrophil elastase
|
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
|
IN2012DN03391A
(enExample)
|
2009-11-18 |
2015-10-23 |
Astrazeneca Ab |
|
|
CN102070608A
(zh)
*
|
2009-11-19 |
2011-05-25 |
天津药物研究院 |
4-取代苯胺基-7-取代烷氧基-喹唑啉衍生物、其制备方法和用途
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
|
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
|
MX2012006776A
(es)
|
2009-12-14 |
2012-10-05 |
Merck Patent Gmbh |
Inhibidores de la esfingosina quinasa.
|
|
CA2784647A1
(en)
|
2009-12-17 |
2011-07-14 |
Merck Patent Gmbh |
Inhibitors of sphingosine kinase
|
|
CN103980337B
(zh)
|
2010-01-15 |
2016-08-24 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
|
KR20120120307A
(ko)
|
2010-01-19 |
2012-11-01 |
아스트라제네카 아베 |
피라진 유도체
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Ｃｄ２０ 항체 및 이의 용도
|
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
|
US9018197B2
(en)
|
2010-08-28 |
2015-04-28 |
Suzhou Neupharma Co. Ltd. |
Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
|
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
|
WO2012067268A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
|
CN103370317B
(zh)
|
2010-12-16 |
2015-10-07 |
阿斯利康(瑞典)有限公司 |
可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
|
|
ES2627433T3
(es)
|
2010-12-17 |
2017-07-28 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivados de purina
|
|
CN102532103B
(zh)
*
|
2010-12-20 |
2014-07-09 |
天津药物研究院 |
喹唑啉芳基脲衍生物及其制备方法和用途
|
|
CN102558160B
(zh)
*
|
2010-12-20 |
2015-09-23 |
天津药物研究院 |
4-取代对甲磺酰胺苯胺基-喹唑啉衍生物及其制备方法和用途
|
|
MX2013007067A
(es)
|
2010-12-20 |
2013-11-01 |
Medimmune Ltd |
Anticuerpos anti-il-18 y sus usos.
|
|
CN103619865B
(zh)
|
2011-02-02 |
2016-10-12 |
苏州润新生物科技有限公司 |
某些化学个体、组合物及方法
|
|
JP5826863B2
(ja)
|
2011-02-15 |
2015-12-02 |
イミュノジェン・インコーポレーテッド |
細胞傷害性ベンゾジアゼピン誘導体
|
|
US20130324532A1
(en)
|
2011-02-17 |
2013-12-05 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
|
US9174946B2
(en)
|
2011-02-17 |
2015-11-03 |
Cancer Therapeutics Crc Pty Ltd |
Selective FAK inhibitors
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
|
SI3255043T1
(sl)
|
2011-07-12 |
2021-04-30 |
Astrazeneca Ab |
N-(6-((2R,3S)-3,4-dihidroksibutan-2-iloksi)-2-(4-fluorobenziltio) pirimidin-4-il)-3-metilazetidin-1-sulfonamid, kot modulator kemokinskega receptorja
|
|
EP4119551A1
(en)
|
2011-07-27 |
2023-01-18 |
Astrazeneca AB |
2-(2,4,5-substituted-anilino)pyrimidine compounds
|
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
|
ES2725790T3
(es)
|
2011-08-26 |
2019-09-27 |
Neupharma Inc |
Algunas entidades químicas, composiciones, y métodos
|
|
WO2013033250A1
(en)
|
2011-09-01 |
2013-03-07 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
|
CN115403531A
(zh)
|
2011-09-14 |
2022-11-29 |
润新生物公司 |
作为激酶抑制剂的化学实体、组合物及方法
|
|
US9249110B2
(en)
|
2011-09-21 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
|
US20140235573A1
(en)
|
2011-09-29 |
2014-08-21 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
|
EP2806874B1
(en)
|
2012-01-25 |
2017-11-15 |
Neupharma, Inc. |
Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
|
|
ES2655264T3
(es)
|
2012-01-28 |
2018-02-19 |
Merck Patent Gmbh |
Derivados de triazolo[4,5-d]pirimidina
|
|
UA116627C2
(uk)
|
2012-02-09 |
2018-04-25 |
Мерк Патент Гмбх |
Похідні тетрагідрохіназоліну як інгібітори tank та parp
|
|
US9045493B2
(en)
|
2012-02-09 |
2015-06-02 |
Merck Patent Gmbh |
Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
|
|
US9073944B2
(en)
|
2012-02-21 |
2015-07-07 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
|
CN104114557B
(zh)
|
2012-02-21 |
2017-10-24 |
默克专利股份公司 |
作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
|
|
CA2863717C
(en)
|
2012-02-21 |
2021-09-28 |
Lars Burgdorf |
Furopyridine derivatives
|
|
US20150051202A1
(en)
|
2012-03-07 |
2015-02-19 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
|
EP2752413B1
(en)
|
2012-03-26 |
2016-03-23 |
Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences |
Quinazoline derivative and application thereof
|
|
CA2868620C
(en)
|
2012-03-28 |
2020-02-25 |
Dieter Dorsch |
Bicyclic pyrazinone derivatives
|
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
|
WO2013150043A1
(en)
|
2012-04-05 |
2013-10-10 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
|
CN104427873B
(zh)
|
2012-04-29 |
2018-11-06 |
润新生物公司 |
某些化学个体、组合物及方法
|
|
AU2013257018B2
(en)
|
2012-05-04 |
2017-02-16 |
Merck Patent Gmbh |
Pyrrolotriazinone derivatives
|
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
US9624264B2
(en)
|
2012-07-24 |
2017-04-18 |
Merck Patent Gmbh |
Hydroxystatin derivatives for the treatment of arthrosis
|
|
JP6374384B2
(ja)
|
2012-08-07 |
2018-08-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
|
|
KR102083154B1
(ko)
|
2012-08-08 |
2020-03-02 |
메르크 파텐트 게엠베하 |
（아자―）이소퀴놀리논 유도체
|
|
CN104736533B
(zh)
|
2012-08-17 |
2016-12-07 |
癌症治疗合作研究中心有限公司 |
Vegfr3抑制剂
|
|
HK1211208A1
(zh)
|
2012-08-22 |
2016-05-20 |
Immunogen, Inc. |
細胞毒性苯並二氮呯衍生物
|
|
EP2890402B1
(en)
|
2012-08-31 |
2019-04-17 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
|
US9688635B2
(en)
|
2012-09-24 |
2017-06-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
RU2650107C2
(ru)
|
2012-09-26 |
2018-04-09 |
Мерк Патент Гмбх |
Производные хиназолинона в качестве ингибиторов parp
|
|
EP2911692B1
(en)
|
2012-10-26 |
2019-08-21 |
The University of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
|
ES2674928T3
(es)
|
2012-11-05 |
2018-07-05 |
Gmdx Co Pty Ltd |
Métodos para determinar la causa de la mutagénesis somática
|
|
WO2014075077A1
(en)
|
2012-11-12 |
2014-05-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
AU2013347232A1
(en)
|
2012-11-16 |
2015-07-02 |
Merck Patent Gmbh |
3-aminocyclopentane carboxamide derivatives
|
|
DK3381917T3
(da)
|
2013-01-31 |
2021-10-18 |
Bellus Health Cough Inc |
Imidazopyridinforbindelser og anvendelser deraf
|
|
JP6321685B2
(ja)
|
2013-02-25 |
2018-05-09 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
|
|
EP3566750A3
(en)
|
2013-02-28 |
2020-04-08 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
JP6423804B2
(ja)
|
2013-02-28 |
2018-11-14 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤を含む複合体
|
|
EP2964648B1
(en)
|
2013-03-05 |
2016-11-16 |
Merck Patent GmbH |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
|
US9937137B2
(en)
|
2013-03-15 |
2018-04-10 |
Neurocentria, Inc. |
Magnesium compositions and uses thereof for cancers
|
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
|
US20160115146A1
(en)
|
2013-06-07 |
2016-04-28 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
|
CA2916533C
(en)
|
2013-06-25 |
2022-12-20 |
University Of Canberra |
Methods and compositions for modulating cancer stem cells
|
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
BR112016005199B1
(pt)
|
2013-08-23 |
2022-02-22 |
Neupharma, Inc |
Certos compostos químicos, composições, e métodos
|
|
ES2851724T3
(es)
|
2013-09-18 |
2021-09-08 |
Epiaxis Therapeutics Pty Ltd |
Modulación de células madre
|
|
EP3052660A4
(en)
|
2013-10-01 |
2017-04-26 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
GB201321146D0
(en)
*
|
2013-11-29 |
2014-01-15 |
Cancer Rec Tech Ltd |
Quinazoline compounds
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
CN105330653A
(zh)
*
|
2014-08-11 |
2016-02-17 |
石药集团中奇制药技术（石家庄）有限公司 |
喹唑啉衍生物
|
|
CA2958704A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
|
ES2883628T3
(es)
|
2014-11-17 |
2021-12-09 |
Univ Queensland |
Biomarcadores de glucoproteínas para adenocarcinoma de esófago y esófago de Barrett y usos de los mismos
|
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
|
EP3270694A4
(en)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
|
USRE49850E1
(en)
|
2015-08-04 |
2024-02-27 |
Aucentra Therapeutics Pty Ltd |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
|
CN105153047A
(zh)
*
|
2015-08-25 |
2015-12-16 |
佛山市赛维斯医药科技有限公司 |
含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
|
|
CN105153046A
(zh)
*
|
2015-08-25 |
2015-12-16 |
佛山市赛维斯医药科技有限公司 |
双卤素取代的乙氧基苯并喹唑啉类酪氨酸激酶抑制剂及用途
|
|
WO2017031551A1
(en)
|
2015-08-26 |
2017-03-02 |
Gmdx Co Pty Ltd |
Methods of detecting cancer recurrence
|
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
|
JP6740354B2
(ja)
|
2015-10-05 |
2020-08-12 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
|
|
GB201519568D0
(en)
|
2015-11-05 |
2015-12-23 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
|
AU2016371466B2
(en)
|
2015-12-17 |
2020-04-09 |
Alonbio Ltd |
Small Molecules for Inhibiting Chemokine Activity and/or Cancer Cells Growth
|
|
EP3390378B1
(en)
|
2015-12-17 |
2022-03-30 |
AlonBio Ltd. |
Small molecules against cancer
|
|
JP7412079B2
(ja)
|
2015-12-23 |
2024-01-12 |
レプルカ プロプライアタリー リミティド |
核酸オリゴマーとその用途
|
|
WO2017122205A1
(en)
|
2016-01-13 |
2017-07-20 |
Hadasit Medical Research Services And Development Ltd. |
Radiolabeled erlotinib analogs and uses thereof
|
|
WO2017132615A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
CN116082457A
(zh)
|
2016-02-01 |
2023-05-09 |
堪培拉大学 |
蛋白化合物及其用途
|
|
GB201604182D0
(en)
|
2016-03-11 |
2016-04-27 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
|
CN108884084A
(zh)
|
2016-03-21 |
2018-11-23 |
阿斯利康(瑞典)有限公司 |
噌啉-4-胺化合物及其在治疗癌症中的用途
|
|
MA44603A
(fr)
|
2016-04-07 |
2019-02-13 |
Astrazeneca Ab |
Oxyde de n,n-diméthyl-3-[[5-(3-méthyl-2-oxo-1-tétrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine utilisé comme modulateur de la protéine kinase atm (ataxia telangiectasia mutated) pour traiter le cancer
|
|
SI3442535T1
(sl)
|
2016-04-15 |
2023-01-31 |
Cancer Research Technology Limited |
Heterociklične spojine kot zaviralci RET-kinaze
|
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
|
GB201608227D0
(en)
|
2016-05-11 |
2016-06-22 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
|
AU2017302635B2
(en)
|
2016-07-29 |
2021-09-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
WO2018035061A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
|
US10919896B2
(en)
|
2016-09-22 |
2021-02-16 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
|
JP7071392B2
(ja)
|
2016-12-05 |
2022-05-18 |
アプロス セラピューティクス， インコーポレイテッド |
酸性基を含有するピリミジン化合物
|
|
JP6883653B2
(ja)
|
2016-12-20 |
2021-06-09 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用
|
|
US11111245B2
(en)
|
2017-02-01 |
2021-09-07 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
|
JOP20190209A1
(ar)
|
2017-03-16 |
2019-09-12 |
Astrazeneca Ab |
مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
|
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
|
US11161839B2
(en)
|
2017-05-26 |
2021-11-02 |
The Institute Of Cancer Research: Royal Cancer Hospital |
2-quinolone derived inhibitors of BCL6
|
|
JP7202315B2
(ja)
|
2017-05-26 |
2023-01-11 |
キャンサー・リサーチ・テクノロジー・リミテッド |
ベンズイミダゾロン由来のｂｃｌ６阻害剤
|
|
PL3630188T3
(pl)
|
2017-05-31 |
2022-01-03 |
Amplio Pharma Ab |
Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
|
|
AU2017422200B2
(en)
|
2017-07-05 |
2022-11-24 |
E.P.O.S Iasis Research And Development Limited |
Multifunctional conjugates
|
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
|
PT3661941T
(pt)
|
2017-08-01 |
2023-03-16 |
Merck Patent Gmbh |
Derivados tiazolopiridina como antagonistas do recetor de adenosina
|
|
WO2019034890A1
(en)
|
2017-08-18 |
2019-02-21 |
Cancer Research Technology Limited |
PYRROLO [2,3-B] PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
|
|
TWI791593B
(zh)
|
2017-08-21 |
2023-02-11 |
德商馬克專利公司 |
做為腺苷受體拮抗劑之苯并咪唑衍生物
|
|
EP3672951B1
(en)
|
2017-08-21 |
2023-08-30 |
Merck Patent GmbH |
Quinoxaline derivatives as adenosine receptor antagonists
|
|
KR20250035037A
(ko)
|
2017-09-18 |
2025-03-11 |
서트로 바이오파마, 인크. |
항-엽산 수용체 알파 항체 접합체 및 이의 용도
|
|
WO2019057757A1
(en)
|
2017-09-20 |
2019-03-28 |
Astrazeneca Ab |
1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
|
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
|
EP3706750A1
(en)
|
2017-11-06 |
2020-09-16 |
RAPT Therapeutics, Inc. |
Chemokine receptor modulators for treatment of epstein barr virus positive cancer
|
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
|
DK3488868T3
(da)
|
2017-11-23 |
2023-11-27 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Farmaceutisk sammensætning til oral indgivelse, som indeholder sulfasalazin og/eller et organisk sulfasalazinsalt, fremstillingsfremgangsmåde samt anvendelse
|
|
EP3740484B1
(en)
|
2018-01-15 |
2024-09-11 |
Aucentra Therapeutics Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
|
DK3743418T3
(da)
|
2018-01-26 |
2024-09-09 |
Rapt Therapeutics Inc |
Chemokinreceptormodulatorer og anvendelser deraf
|
|
AU2019218893B2
(en)
|
2018-02-08 |
2024-12-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP3762379A1
(en)
|
2018-03-07 |
2021-01-13 |
Bayer Aktiengesellschaft |
Identification and use of erk5 inhibitors
|
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
|
CA3095371A1
(en)
|
2018-04-13 |
2019-10-17 |
Cancer Research Technology Limited |
Bcl6 inhibitors
|
|
EP4643950A3
(en)
|
2018-04-27 |
2026-01-14 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
|
TW202003475A
(zh)
|
2018-06-04 |
2020-01-16 |
美商亞博創新醫藥有限公司 |
含酸性基團之嘧啶化合物
|
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
|
CN115636833B
(zh)
|
2018-09-14 |
2024-11-29 |
苏州赞荣医药科技有限公司 |
作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
|
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
|
EP4523755A3
(en)
|
2018-09-18 |
2025-06-11 |
F. Hoffmann-La Roche AG |
Quinazoline derivatives as antitumor agents
|
|
US11084829B2
(en)
|
2018-09-24 |
2021-08-10 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
|
|
KR20210083287A
(ko)
|
2018-10-25 |
2021-07-06 |
메르크 파텐트 게엠베하 |
아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
|
|
KR20210083293A
(ko)
|
2018-10-25 |
2021-07-06 |
메르크 파텐트 게엠베하 |
아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
|
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
ES3031988T3
(en)
|
2018-12-25 |
2025-07-14 |
Beijing Baishihekang Pharmaceutical Tech Bsjpharma Co Ltd |
Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
|
|
KR102334943B1
(ko)
*
|
2018-12-28 |
2021-12-06 |
한국화학연구원 |
신규 이소퀴놀린 유도체, 이의 제조방법, 및 이를 유효성분으로 함유하는 오토파지 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
|
JP7578602B2
(ja)
|
2019-02-25 |
2024-11-06 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド |
Ｐ２ｘ３修飾薬での治療
|
|
US11033547B2
(en)
|
2019-03-07 |
2021-06-15 |
Merck Patent Gmbh |
Carboxamide-pyrimidine derivatives as SHP2 antagonists
|
|
ES3001119T3
(es)
|
2019-03-28 |
2025-03-04 |
Amplia Therapeutics Ltd |
Una sal y forma cristalina de un inhibidor de FAK
|
|
CA3133766A1
(en)
|
2019-03-29 |
2020-10-08 |
Astrazeneca Ab |
Osimertinib for use in the treatment of non-small cell lung cancer
|
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
|
WO2020201773A1
(en)
|
2019-04-05 |
2020-10-08 |
Storm Therapeutics Ltd |
Mettl3 inhibitory compounds
|
|
JP7586834B2
(ja)
|
2019-04-08 |
2024-11-19 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｈｐ２拮抗薬としてのピリミジノン誘導体
|
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
|
ES3014809T3
(en)
|
2019-05-15 |
2025-04-25 |
Alonbio Ltd |
Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
|
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
|
WO2021037219A1
(zh)
|
2019-08-31 |
2021-03-04 |
上海奕拓医药科技有限责任公司 |
用于fgfr抑制剂的吡唑类衍生物及其制备方法
|
|
JP2022548690A
(ja)
|
2019-09-20 |
2022-11-21 |
アイディアヤ バイオサイエンシーズ，インコーポレイティド |
Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体
|
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
CN115151540A
(zh)
|
2019-12-02 |
2022-10-04 |
风暴治疗有限公司 |
作为mettl3抑制剂的多杂环化合物
|
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
|
WO2022074391A1
(en)
|
2020-10-08 |
2022-04-14 |
Storm Therapeutics Limited |
Compounds inhibitors of mettl3
|
|
EP3992191A1
(en)
|
2020-11-03 |
2022-05-04 |
Deutsches Krebsforschungszentrum |
Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
|
|
WO2022179608A1
(zh)
*
|
2021-02-25 |
2022-09-01 |
石药集团中奇制药技术（石家庄）有限公司 |
多靶点蛋白激酶抑制剂的用途
|
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
AU2021433713A1
(en)
|
2021-03-17 |
2023-09-28 |
Suzhou Zanrong Pharma Limited |
Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
|
|
WO2022232488A1
(en)
|
2021-04-30 |
2022-11-03 |
Celgene Corporation |
Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
|
|
JP2024517872A
(ja)
|
2021-05-03 |
2024-04-23 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ＨＥＲ２を標的にするＦｃ抗原結合性フラグメント－薬物抱合体
|
|
KR102733257B1
(ko)
|
2021-05-17 |
2024-11-26 |
에이치케이이노엔 주식회사 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
IL308818A
(en)
|
2021-05-25 |
2024-01-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
|
US11878013B2
(en)
|
2021-07-02 |
2024-01-23 |
Korea Research Institute Of Chemical Technology |
Isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient
|
|
US20250002491A1
(en)
|
2021-10-04 |
2025-01-02 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
|
IL312004A
(en)
|
2021-10-20 |
2024-06-01 |
Hoffmann La Roche |
Crystalline forms of quinazoline derivatives, their preparation, assembly and use
|
|
AU2023205435A1
(en)
|
2022-01-10 |
2024-08-22 |
Cancer Research Horizons |
Substituted heterocycles as hset inhibitors
|
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
|
WO2023186881A1
(en)
|
2022-03-29 |
2023-10-05 |
Baden-Württemberg Stiftung Ggmbh |
P38 map kinase inhibitors for use in the treatment of colorectal cancer
|
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
|
US12240837B2
(en)
|
2022-04-06 |
2025-03-04 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
|
CA3259758A1
(en)
|
2022-06-30 |
2024-01-04 |
Sutro Biopharma, Inc. |
Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates
|
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
KR20250073643A
(ko)
|
2022-10-03 |
2025-05-27 |
포알엑스 테라퓨틱스 아게 |
Parg 억제 화합물
|
|
CN115650827B
(zh)
*
|
2022-10-27 |
2024-03-15 |
戊言医药科技（上海）有限公司 |
用于一类蒽环类毒素衍生物的制备方法、中间体化合物及合成方法
|
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
|
EP4612149A1
(en)
|
2022-11-02 |
2025-09-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
|
CN120265629A
(zh)
|
2022-11-07 |
2025-07-04 |
默克专利股份公司 |
被取代的双环和三环hset抑制剂
|
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
CN118103373A
(zh)
|
2023-01-18 |
2024-05-28 |
上海德琪医药科技有限公司 |
Prmt5抑制化合物和其用途
|
|
WO2024173514A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Amide and ester-substituted imidazopyridine compounds
|
|
WO2024173530A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
|
|
WO2024173453A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted imidazopyridine compounds
|
|
WO2024173524A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted benzimidazole compounds
|
|
KR20250153866A
(ko)
|
2023-03-10 |
2025-10-27 |
브레이크포인트 테라퓨틱스 게엠베하 |
Dna 중합효소 세타 억제제
|
|
EP4434972A1
(en)
|
2023-03-22 |
2024-09-25 |
Eberhard-Karls-Universität Tübingen |
Atm kinase inhibitors
|
|
EP4688159A1
(en)
|
2023-04-05 |
2026-02-11 |
FoRx Therapeutics AG |
Parg inhibitory compounds
|
|
GB2631509A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
|
GB2631507A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
|
WO2025046148A1
(en)
|
2023-09-01 |
2025-03-06 |
Forx Therapeutics Ag |
Novel parg inhibitors
|
|
WO2025056923A1
(en)
|
2023-09-15 |
2025-03-20 |
Cambridge Enterprise Limited |
Combination therapy
|
|
WO2025073792A1
(en)
|
2023-10-02 |
2025-04-10 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
GB202315149D0
(en)
|
2023-10-03 |
2023-11-15 |
Celleron Therapeutics Ltd |
Combination therapy
|
|
CN121889393A
(zh)
|
2023-10-03 |
2026-04-17 |
福克斯治疗股份公司 |
Parg抑制化合物
|
|
AU2024358957A1
(en)
|
2023-10-13 |
2026-04-02 |
Sutro Biopharma, Inc. |
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
|
|
GB202316595D0
(en)
|
2023-10-30 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
GB202316683D0
(en)
|
2023-10-31 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025093755A1
(en)
|
2023-11-01 |
2025-05-08 |
Forx Therapeutics Ag |
Novel parc inhibitors
|
|
GB202317368D0
(en)
|
2023-11-13 |
2023-12-27 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
|
WO2025104443A1
(en)
|
2023-11-14 |
2025-05-22 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025114480A1
(en)
|
2023-11-28 |
2025-06-05 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
AR134697A1
(es)
|
2023-12-18 |
2026-03-04 |
Ideaya Biosciences Inc |
Compuestos químicos y sus usos
|
|
GB202319864D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202319863D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Movel compounds, compositions and therapeutics uses thereof
|
|
WO2025133395A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Bicyclic (hetero)arylene wrn inhibitory compounds
|
|
WO2025133396A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Novel bicyclo heteroaryl parg inhibitors
|
|
WO2025191176A1
(en)
|
2024-03-14 |
2025-09-18 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
NL2037411B1
(en)
|
2024-04-08 |
2025-10-31 |
Univ Leiden |
Protac compounds
|
|
WO2025250825A1
(en)
|
2024-05-30 |
2025-12-04 |
Sutro Biopharma, Inc. |
Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
|
|
GB202407738D0
(en)
|
2024-05-31 |
2024-07-17 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025262192A1
(en)
|
2024-06-21 |
2025-12-26 |
Breakpoint Therapeutics Gmbh |
Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
|
|
WO2026003380A1
(en)
|
2024-06-28 |
2026-01-02 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2026022150A1
(en)
|
2024-07-22 |
2026-01-29 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
|
WO2026043823A2
(en)
|
2024-08-19 |
2026-02-26 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
|
|
WO2026062066A1
(en)
|
2024-09-17 |
2026-03-26 |
Forx Therapeutics Ag |
Compounds inducing parg degradation
|
|
WO2026080697A1
(en)
|
2024-10-09 |
2026-04-16 |
Sutro Biopharma, Inc. |
Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use
|